Merck & Co

Merck & Co to buy Prometheus Biosciences for nearly $11 billion

The company, through one of its subsidiaries, will pay $200 per share for Prometheus Biosciences

Merck Covid pill gains US clearance for high-risk adults

Molnupiravir, developed by Merck with partner Ridgeback Biotherapeutics LP, is intended to treat Covid in nonhospitalized people 18 and older at risk of developing severe illness

US FDA panel narrowly backs Covid-19 pill, world's first at-home treatment

Permission for Merck & Co's antiviral treatment would likely be limited to patients at high risk of developing severe disease, although the exact population would be defined by the agency.

India's Everest Organics starts making ingredient for Merck's Covid pill

The Indian bulk drugs manufacturer joins Divi's Laboratories Ltd as an API maker for Merck's experimental oral drug

A step from Covid-19 pills as Merck & Co seeks FDA approval

An application was submitted with the Food and Drug Administration for molnupiravir to treat mild-to-moderate Covid-19 in adults at risk of developing a severe illness that may require hospitalization

Merck to buy Acceleron Pharma in deal valued at $11.5 billion

Acceleron shareholders will get $180 a share in cash, the companies said in a statement.

Merck sees recovery in non-Covid vax demand, quarterly sales beat estimates

(Reuters) - Merck & Co reported quarterly revenue on Thursday that topped Wall Street estimates, as sales of its Gardasil vaccine bounced back and demand for blockbuster cancer drug Keytruda remained strong.

Hetero seeks emergency use authorisation for Merck's antiviral drug

Clinical trial shows molnupiravir helps in early recovery in non-hospitalised Covid-19 patients

Merck taps five Indian drugmakers to expand Covid-19 drug production

Merck has decided to focus on its drugs for Covid after two vaccines failed to generate desired immune responses

Drugmaker Merck divests stake in vaccine-maker Moderna after stock surge

(Reuters) - U.S. drugmaker Merck & Co said on Wednesday it has sold its equity investment in Moderna Inc, after benefiting from a surge in the stock price of the vaccine developer this year.

Merck says early data from Covid-19 vaccines expected this year

Initial data showing whether V591 triggers an immune response in trial participants is expected by the end of the year

Second-generation Covid-19 vaccines are built for impact over speed

Some of the world's most prolific and experienced vaccine developers -- Sanofi, GlaxoSmithKline and Merck & Co - are among at least 100 challengers trailing the leaders

Germany's Merck mull over sale of biosimilar drug business: Sources

Merck's biosimilars business could be worth as much as $1 billion because of its long-term sales potential.

Merck, Pfizer double size of diabetes study to catch rivals

The pharmaceutical companies are developing the drug ertugliflozin for use alone and in combination with Merck's best-selling Januvia